Article

QLT lowers verteporfin cost after CMS cuts reimbursement

Toronto-QLT Inc. is temporarily lowering the price of verteporfin (Visudyne, Novartis and QLT Inc.) by $55 after the Centers for Medicare & Medicaid Services (CMS) lowered the amount for which it would reimburse physicians.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
Related Content
Most patients support AI in health care if it means more time with doctors
June 30th 2025

Most patients support AI in health care if it means more time with doctors

Commercial real estate and your practice, part two with Colin Carr
May 21st 2022

Commercial real estate and your practice, part two with Colin Carr

Pathways for better care: When patients and providers move in sync
June 18th 2025

Pathways for better care: When patients and providers move in sync

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)
May 12th 2022

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Nextech and Ocuco partner to deliver seamless end-to-end eyecare platform
April 13th 2025

Nextech and Ocuco partner to deliver seamless end-to-end eyecare platform

(Image credit: AdobeStock/iQoncept)
March 26th 2025

Beyond mentoring: The power of sponsorship and advocacy in ophthalmology

© 2025 MJH Life Sciences

All rights reserved.